Dr. Faubel nailed the best comment about NephroCheck by reminding us while we pick apart the particulars of NephroCheck that we have some other dragons to slay:
And then Edgar slides in with the appropriate #NephPearl (How does he do that so fast?)
2025 was rich in successful stories. Here are the top 10 that impressed our audience.
This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.
Holy Mackerel! This week we will discuss fish oil use in maintenance hemodialysis patients. Could this be the one thing that bends the curve on CV mortality, or is it just a red herring?
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
Dr. Faubel nailed the best comment about NephroCheck by reminding us while we pick apart the particulars of NephroCheck that we have some other dragons to slay:
@hswapnil @Nephro_Sparks @dr_nikhilshah btw, nephrocheck and urine eos cost about the same. urine eos useless. this much better. #nephjc
— sarah faubel (@doc_faubel) February 18, 2015
And then Edgar slides in with the appropriate #NephPearl (How does he do that so fast?)
@NephJC @doc_faubel Why I DO NOT order URINE EOSINOPHILS anymore #Nephpearls #NephJC http://t.co/NH9PdFK7fc pic.twitter.com/cbneNsoZPl
— Edgar V. Lerma (@edgarvlermamd) February 18, 2015
We had a great NephJC last night. We had a new contributor who was excellent, Eric Weinhandl of Minnesota.
those models for ESRD risk are like spinning plates. 31 events and HRs bounce around with every adjustment #nephjc
— Eric Weinhandl (@EWeinhandl) February 4, 2015
Dr. Weinhandl works with the new PEER Kidney Care Initiative. It looks like a cool project. Here is some press from Nephrology News and Issues.